Hayden E. Klein

A new study revealed longer heart failure hospital stays, better 30-day follow-up, and lower mortality rates in Japan compared with the US.

Older adults with the most irregular sleep durations demonstrated a 34% higher risk of developing type 2 diabetes compared with those with the most regular sleep.

New studies say restricting salt intake can reduce the risk of atrial fibrillation (AF) in certain patients, but cannot reduce the risks of morbidity and death in patients with heart failure.

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.

The aflibercept 8 mg injection improves patient care by allowing longer intervals between treatments, explains Jose A. Martinez, MD, Austin Retina Associates.

The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields.

Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center, emphasizes the importance of bringing heart health care to patients and meeting them where they are.

Among patients with type 2 diabetes, glucagon-like peptide 1 (GLP-1) receptor agonists reduced their risk of obesity-related cancers more than insulin did.

Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF).

However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.

The complete response letter (CRL) was not related to safety or efficacy data, but was a result of inspection findings at a third-party manufacturing facility.

The FDA approved epcoritamab-bysp to treat adults with relapsed or refractory (R/R) follicular lymphoma after 2 or more lines of systemic therapy.

More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.

The ENV-101 phase 2a trial for idiopathic pulmonary fibrosis (IPF) focused on assessing safety, lung function, and fibrosis, with plans for further trials, combination therapies, and strategies to manage adverse effects.

The University Hospitals CINEMA program aims to address issues and narrow gaps in obesity management, with a focus on meeting patients where they are and providing them tools for success, says Ian Neeland, MD.

Robert Lustig, MD, MSL, explains how the US health care industry needs to shift from measuring body mass index and obesity to measuring cardiometabolic health, which affects 93% of Americans, including children.

Taking falsified semaglutide (Ozempic; Novo Nordisk) can lead to ineffective treatment due to incorrect dosing, contamination, and the use of unknown ingredients, the World Health Organization (WHO) is warning.

Patients with diabetes who have private insurance are more likely to be prescribed a continuous glucose monitor (CGM) compared with those with government insurance, says Chase Hendrickson, MD, MPH, Vanderbilt University Medical Center.

Patients with the highest biologically active adrenomedullin (bio-ADM) levels at baseline were 114% more likely to die from any cause or be readmitted to the hospital for heart failure within 6 months compared with patients with the lowest levels.

It’s important for clinicians to listen to patients and know how heart disease may affect women differently than men, said Kathryn Lindley, MD, FACC, Vanderbilt University Medical Center.

Adults aged 70 and older were significantly more likely to develop congestive heart failure if they also experienced olfactory impairment.

John Hood, PhD, cofounder and CEO of Endeavor BioMedicines, explains the potential advantages of ENV-101 during a time with very few treatments for idiopathic pulmonary fibrosis (IPF).

Children aged 10 years and older with type 2 diabetes can now improve their glycemic control with a drug previously only approved for adults.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed challenges in Duchenne muscular dystrophy (DMD) treatment access and how policy changes may support patients with DMD.

The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.

Jeff Levin-Scherz, MD, MBA, population health leader at WTW, explains that obesity care in the US is inconsistent and costly, with significant gaps across Medicare, Medicaid, and employer-based insurance.

Ronesh Sinha, MD, attributes the rising rates of heart disease to sedentary lifestyles, stress, and health inequities, while advocating for digital health solutions to improve preventive care.

According to new research from Jordan, patients with both heart failure (HF) and diabetes had a higher prevalence of HF with preserved ejection fraction (HFpEF), elevated cholesterol, low-density lipoprotein, and impaired kidney function.

Cardiovascular disease (CVD) risk was reduced by 1.2% in the intention-to-treat analysis and 5% in the per protocol analysis for adults aged 75 and older.

Migvis Monduy, MD, medical director of Neuromuscular and Movement Disorders Programs at Nicklaus Children's Hospital, discussed the most promising areas of research in Duchenne muscular dystrophy (DMD), as well as the mechanisms of gene therapies for DMD.